Esperion Therapeutics, Inc. (ESPR) Given Consensus Rating of “Buy” by Brokerages
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned an average recommendation of “Buy” from the fifteen analysts that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $60.73.
A number of research analysts have weighed in on the company. Northland Securities restated a “buy” rating and issued a $72.00 price objective on shares of Esperion Therapeutics in a report on Friday. Stifel Nicolaus restated a “buy” rating and issued a $70.00 price objective on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Cowen and Company assumed coverage on Esperion Therapeutics in a report on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price objective on the stock. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, Jefferies Group LLC restated a “buy” rating and issued a $85.00 price objective on shares of Esperion Therapeutics in a report on Monday, August 21st.
Hedge funds have recently bought and sold shares of the stock. Emory University purchased a new stake in Esperion Therapeutics during the second quarter worth approximately $2,164,000. Dimensional Fund Advisors LP lifted its stake in Esperion Therapeutics by 174.7% during the first quarter. Dimensional Fund Advisors LP now owns 110,475 shares of the biopharmaceutical company’s stock worth $3,901,000 after purchasing an additional 70,255 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in Esperion Therapeutics during the second quarter worth approximately $1,182,000. Meditor Group Ltd lifted its stake in Esperion Therapeutics by 305.5% in the third quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock valued at $115,022,000 after buying an additional 1,728,935 shares during the last quarter. Finally, BB Biotech AG lifted its stake in Esperion Therapeutics by 7.5% in the second quarter. BB Biotech AG now owns 1,513,542 shares of the biopharmaceutical company’s stock valued at $70,047,000 after buying an additional 105,000 shares during the last quarter. Hedge funds and other institutional investors own 89.12% of the company’s stock.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same quarter in the previous year, the business earned ($0.77) EPS. equities analysts expect that Esperion Therapeutics will post -7.21 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/13/esperion-therapeutics-inc-espr-given-consensus-rating-of-buy-by-brokerages.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.